June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
The results of intravitreal bevacizumab (Avastin) therapy in patients with retinal venous occlusion
Author Affiliations & Notes
  • Zsofia Kolkedi
    Department of Ophthalmology, University of Pécs, Pécs, Hungary
  • Adrienn Horváth
    Department of Ophthalmology, University of Pécs, Pécs, Hungary
  • Zsolt Biro
    Department of Ophthalmology, University of Pécs, Pécs, Hungary
  • Footnotes
    Commercial Relationships Zsofia Kolkedi, None; Adrienn Horváth, None; Zsolt Biro, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1811. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Zsofia Kolkedi, Adrienn Horváth, Zsolt Biro; The results of intravitreal bevacizumab (Avastin) therapy in patients with retinal venous occlusion. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1811.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the functional and anatomical results of anti-VEGF (bevacizumab) treatment in patients with retinal venous occlusion.<br />

Methods: Retrospective data analysis of 20 patients (10 men, 10 women, mean age 62 years) suffering from retinal venous occlusion (10 CRVO, 10 BRVO) treated with intravitreal bevacizumab injections at the Department of Ophthalmology, Faculty of Medicine, University of Pécs, Hungary between July 2012 and May 2014. The mean follow-up time was 12 (5-22) months. The visual acuity was determined by ETDRS chart, the retinal thickness by SD OCT (Topcon).

Results: The mean best corrected visual acuity improved by 15 ETDRS letters (from 55 to 70). The central retinal thickness decreased from 521 µms to 322 µms in average by the end of the follow-up period. The mean number of injections was 7 during the follow-up time.

Conclusions: Intravitreal bevacizumab therapy in patients with retinal venous occlusion showed functional and anatomical results during one year follow up.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×